NICE has published technology appraisal guidance TA1152 recommending semaglutide (Wegovy) as an option for reducing the risk of a major adverse cardiovascular event (MACE) in a tightly defined adult population: established cardiovascular disease plus a body-mass index of at least 27 kg/m². The guidance was published on 7 May 2026. It is distinct from NICE's existing obesity appraisals for semaglutide (TA875) and tirzepatide (TA1026). Type 2 diabetes is not an eligibility criterion.

This is a recommendation about a licensed prescription-only medicine. It is not a finding about unlicensed research peptides, and it is not consumption, self-administration or dosing advice. Peptide Data reports the appraisal because it changes how a GLP-1 receptor agonist is positioned in UK medicines policy — as cardiovascular secondary prevention, not solely as a weight-management or diabetes drug.

1. What NICE actually recommended

Recommendation 1.1 states that semaglutide, up to a maintenance dose of 2.4 mg once weekly and within its marketing authorisation, can be used alongside a reduced-calorie diet and increased physical activity as an option for reducing the risk of MACE — defined as cardiovascular death, non-fatal myocardial infarction or non-fatal stroke — in adults who have both of the following:

  • established cardiovascular disease, defined as at least one of: previous myocardial infarction; previous ischaemic or haemorrhagic stroke; or symptomatic peripheral arterial disease (intermittent claudication with an ankle-brachial index of less than 0.85 at rest, or a previous peripheral arterial revascularisation procedure, or an amputation because of atherosclerotic disease); and
  • a BMI of at least 27 kg/m².

Use is conditional on the company providing the product according to the commercial arrangement recorded in the appraisal. NICE's practice note is unambiguous: there is enough evidence that semaglutide "provides benefits and value for money, so it can be used routinely across the NHS in this population." The guidance does not specify the care setting in which it should be initiated.

Under the NHS Constitution funding rule that attaches to positive technology appraisals, semaglutide must be funded in England within 90 days of final publication where a clinician considers it the most suitable option for a person in the recommended population. From a 7 May 2026 publication date, that clock ran to early August 2026.

2. The SELECT evidence the committee relied on

The clinical case is the SELECT trial: a multinational, randomised, double-blind, placebo-controlled cardiovascular-outcomes study of once-weekly subcutaneous semaglutide 2.4 mg versus placebo, added to standard care, in 17,604 adults aged 45 years or over with overweight or obesity (BMI ≥27 kg/m²), established cardiovascular disease, and no diabetes. The primary endpoint was time to first MACE (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke).

Lincoff and colleagues reported a hazard ratio of 0.80 (95% confidence interval 0.72 to 0.90; p < 0.001). First MACE occurred in 6.5% of participants assigned to semaglutide and 8.0% assigned to placebo. Mean follow-up was in the region of 40 months. Gastrointestinal adverse events were the principal reason that discontinuations were more common with semaglutide than with placebo (16.6% versus 8.2% in the published safety analysis); serious adverse events were not more frequent with semaglutide (33.4% versus 36.4%).

NICE's committee language is more conservative than the sponsor narrative. The published recommendation says only that clinical trial evidence shows semaglutide plus standard care reduces MACE risk compared with placebo plus standard care in this population, and that cost-effectiveness estimates fall within the range NICE considers an acceptable use of NHS resources. It does not rest the recommendation on claims that the MACE reduction is independent of weight change. A 2025 prespecified SELECT analysis in The Lancet examined MACE by baseline and change in adiposity; that analysis is not the basis of TA1152 and is not re-interpreted here.

3. How TA1152 differs from the obesity appraisals

Two related NICE appraisals remain in force and should not be collapsed into this one.

  • TA875 (semaglutide for managing overweight and obesity) is a weight-management appraisal, implemented through specialist weight-management services with a time-limited course. TA1152 is a cardiovascular secondary-prevention appraisal. It does not require type 2 diabetes, does not route prescribing exclusively through specialist weight-management services, and does not use the TA875 BMI and comorbidity thresholds.
  • TA1026 (tirzepatide for managing overweight and obesity) is likewise a weight-management appraisal, with NHS England interim commissioning guidance and a phased rollout. Tirzepatide does not, as of this writing, have a parallel NICE technology appraisal for MACE reduction in people with established CVD and overweight or obesity without diabetes. SURMOUNT-5 compared tirzepatide with semaglutide on weight; it was not a cardiovascular-outcomes trial.

NHS England has estimated that around 1.2 million people in England could be eligible for the cardiovascular indication over the coming years. That figure is a commissioning estimate, not a NICE numerator, and should be read as such. The same announcement placed the option alongside — not instead of — existing secondary-prevention medicines such as statins and antihypertensives.

4. Scotland, Wales and Northern Ireland

NICE technology appraisals apply in England. Wales generally adopts NICE TAs; local implementation still depends on health-board formulary processes.

On 8 June 2026 the Scottish Medicines Consortium accepted semaglutide (Wegovy), as SMC2872, for use alongside diet and exercise to reduce the risk of major cardiovascular events in adults with a BMI of 27 kg/m² or more and cardiovascular disease. The public summary states that the medicine is available for prescribing on NHS Scotland, taking into account a confidential discount. SMC decisions are independent of NICE; the eligibility line in SMC2872 is nonetheless aligned with TA1152.

Northern Ireland has its own adoption process for NICE TAs. Researchers and clinicians should check the current circular rather than assume simultaneous availability.

5. UK legal status: a licensed POM, not a research peptide

Semaglutide 2.4 mg (Wegovy) is a prescription-only medicine under the Human Medicines Regulations 2012, with a UK marketing authorisation held by Novo Nordisk. Supply other than in accordance with that authorisation — including unlicensed "research" presentations sold as semaglutide — is a separate legal question under the Medicines Act 1968 and the 2012 Regulations. TA1152 does not legalise, grade or otherwise speak to unlicensed research peptides.

The MHRA remains the UK regulator for safety of the licensed products. Existing Drug Safety Updates on this class still apply: acute pancreatitis, including rare necrotising and fatal cases (January 2026); very rare non-arteritic anterior ischaemic optic neuropathy with semaglutide (February 2026); pulmonary aspiration risk before anaesthesia or deep sedation (January 2025); and the February 2026 identification of falsified Mounjaro (tirzepatide) 15 mg KwikPens. Suspected adverse reactions should be reported through the Yellow Card scheme. None of those signals is re-opened by TA1152; they sit alongside it.

6. What this does not mean

TA1152 is an NHS funding and clinical-option decision for a licensed indication. It does not:

  • authorise unlicensed semaglutide, tirzepatide or other incretin mimetics sold as research chemicals;
  • alter evidence grades on Peptide Data compound profiles for unlicensed research peptides;
  • imply that GLP-1, dual GIP/GLP-1 or triple agonists as a class have a NICE-endorsed cardiovascular indication — the recommendation is product- and population-specific;
  • replace standard secondary-prevention care (lipid modification, blood-pressure control, antiplatelet therapy where indicated, smoking cessation);
  • constitute dosing, reconstitution or self-administration guidance for any reader.

For the licensed product, the maintenance dose cited above is the dose specified in NICE recommendation 1.1 and in the UK marketing authorisation. It is reported here as a regulatory fact. It is not a protocol.

The practical consequence for this reference is narrow and documentary: semaglutide now has a NICE-recommended cardiovascular secondary-prevention use in a BMI-defined, CVD-defined adult population, with a 90-day NHS England funding obligation from 7 May 2026 and a parallel SMC acceptance in Scotland. That is a change in UK medicines policy. It is not a change in the research-use-only line that governs unlicensed peptides.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.